Published

Psilocybin-assisted psychotherapy for psycho-existential distress in advanced cancer: a narrative review.

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: BMJ supportive & palliative care
Date: 2026-04-28
Source: PubMed
DOI: 10.1136/spcare-2025-005689
PubMed: 41708300

Authors

Magnani L Ghirotto L Fesce F Re T Tanzi S Amerio A Costanza A

Watch author

Derived topics and classifications

psilocybin Depression Anxiety End-of-Life Distress Chronic Pain Pharmacology Review Article Cancer Patients Inflammation Review Article

Citation graph

0 referenced DOIs found in stored source metadata. 0 indexed papers cite this DOI.

Open citation network

Related papers

Psilocybin-Assisted Therapy in Psychiatry: A Narrative Clinical Review of Mechanisms, Therapeutic Applications, and Emerging Evidence (2025-2026)Journal of Clinical Medicine · 2026-08-12 Current status and future prospects of research on psilocybin's regulation of neurotransmitters and their receptors related to the pathogenesis of tinnitus.Hearing research · 2026-08-01 Group Retreat Psilocybin Therapy for People with Metastatic Cancer with Anxiety and Depression: A Rite of Passage Facilitation Model for a Phase 1/2 Study.Psychedelic medicine (New Rochelle, N.Y.) · 2026-09-01 Assessing Canadian Policy Readiness for Psychedelic-Assisted Therapy in Cancer CareUnknown journal · 2026-08-17 Safety and Efficacy of Psilocybin During Anticancer Treatment: A Phase II Trial Secondary Analysis.Journal of pain and symptom management · 2026-08-03 Participants' Music Experiences Associated With Psychedelic-Assisted Psychotherapy for Life-Threatening Illness: Interpretivist Research.Journal of music therapy · 2026-07-24 Psychedelic Therapies in the Management of Post-Traumatic Stress DisorderJournal of Education Health and Sport · 2026-07-16 Mindfulness-Based Psilocybin-Assisted Therapy (MB-PAT) for cancer-related demoralization in Canada: The case for a hybrid group-based delivery modelPsychedelics · 2026-12-01